NASDAQ:ACHL Achilles Therapeutics - ACHL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $0.88 +0.03 (+3.53%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.86▼$0.9050-Day Range$0.84▼$1.2652-Week Range$0.75▼$3.45Volume90,240 shsAverage Volume383,808 shsMarket Capitalization$36.02 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Achilles Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside1,036.5% Upside$10.00 Price TargetShort InterestHealthy0.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.79) to ($1.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 starsMedical Sector228th out of 995 stocksBiological Products, Except Diagnostic Industry39th out of 166 stocks 3.3 Analyst's Opinion Consensus RatingAchilles Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Achilles Therapeutics has a forecasted upside of 1,036.5% from its current price of $0.88.Amount of Analyst CoverageAchilles Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.02% of the float of Achilles Therapeutics has been sold short.Short Interest Ratio / Days to CoverAchilles Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Achilles Therapeutics has recently decreased by 33.68%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAchilles Therapeutics does not currently pay a dividend.Dividend GrowthAchilles Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACHL. Previous Next 2.5 News and Social Media Coverage News SentimentAchilles Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Achilles Therapeutics this week, compared to 0 articles on an average week.Search Interest7 people have searched for ACHL on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Achilles Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.38% of the stock of Achilles Therapeutics is held by insiders.Percentage Held by Institutions69.66% of the stock of Achilles Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Achilles Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achilles Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achilles Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchilles Therapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Achilles Therapeutics (NASDAQ:ACHL) StockAchilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.Read More Receive ACHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACHL Stock News HeadlinesMarch 27, 2023 | americanbankingnews.comCritical Analysis: Achilles Therapeutics (NASDAQ:ACHL) and Quince Therapeutics (NASDAQ:QNCX)March 24, 2023 | health.usnews.comGerard Achilles M. ObnialMarch 28, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 7, 2023 | finanznachrichten.deAchilles Therapeutics PLC: Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business HighlightsMarch 7, 2023 | finance.yahoo.comAchilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business HighlightsJanuary 17, 2023 | finance.yahoo.comIs Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?December 20, 2022 | finance.yahoo.comAchilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 6, 2022 | finance.yahoo.comAchilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022March 28, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastNovember 30, 2022 | finance.yahoo.comAchilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022November 22, 2022 | finance.yahoo.comAchilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary MethodNovember 13, 2022 | finance.yahoo.comIs Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?November 8, 2022 | finance.yahoo.comAchilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business HighlightsOctober 6, 2022 | finance.yahoo.comAchilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell TherapySeptember 26, 2022 | nasdaq.comAchilles Therapeutics plc (NASDAQ:ACHL) stock most popular amongst private equity firms who own 51%, while individual investors hold 22%September 12, 2022 | reuters.comAchilles Therapeutics PLCSeptember 7, 2022 | finance.yahoo.comGilead's (GILD) Tecartus Gets EC Nod for New Cancer IndicationAugust 31, 2022 | finance.yahoo.comCuris (CRIS) Gets FDA Nod to Partly Resume Leukemia StudyAugust 25, 2022 | finance.yahoo.comAstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 DrugsAugust 16, 2022 | finance.yahoo.comHorizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914August 9, 2022 | finance.yahoo.comAchilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business HighlightsAugust 1, 2022 | finance.yahoo.comWhat Is The Ownership Structure Like For Achilles Therapeutics plc (NASDAQ:ACHL)?July 6, 2022 | morningstar.comAchilles Therapeutics PLC ADR - Stock Quote ACHLJune 30, 2022 | finanznachrichten.deAchilles Therapeutics PLC: Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory BoardJune 30, 2022 | finance.yahoo.comAchilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory BoardJune 21, 2022 | finance.yahoo.comAchilles Therapeutics Recognized with the 2022 PING Innovation AwardJune 6, 2022 | finance.yahoo.comHere's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn SituationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACHL Company Calendar Last Earnings11/08/2021Today3/27/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACHL CUSIPN/A CIK1830749 Webwww.achillestx.com Phone44-0-20-8154-4600FaxN/AEmployees242Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+809.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.72% Return on Assets-28.54% Debt Debt-to-Equity Ratio0.02 Current Ratio10.93 Quick Ratio10.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.03 per share Price / Book0.17Miscellaneous Outstanding Shares40,940,000Free Float38,736,000Market Cap$36.02 million OptionableNot Optionable Beta0.98 Key ExecutivesDr. Iraj Ali (Age 46)CEO & Director Dr. Karl Peggs M.D. (Age 55)Founder & Chief Medical Officer Dr. Mark William Lowdell BSc (Age 59)FRCPath, MICR, MSc, Ph.D., Founder Dr. Charles Swanton FMEDSCI (Age 49)M.D., Ph.D., Founder Dr. Sergio A. Quezada Ph.D. (Age 46)Founder & Chief Scientific Officer Mr. Robert Coutts (Age 38)Chief Financial Officer Mr. Lee M. SternVP of Investor Relations & External CommunicationsMr. Daniel HoodGen. Counsel & Company Sec.Julia WilsonHead of CommunicationsMr. Tariq AhmedVP of PeopleMore ExecutivesKey CompetitorsSurrozenNASDAQ:SRZNPluriNASDAQ:PLUROKYO PharmaNASDAQ:OKYOAxcella HealthNASDAQ:AXLAMiromatrix MedicalNASDAQ:MIROView All CompetitorsInstitutional OwnershipMillennium Management LLCBought 81,755 shares on 2/15/2023Ownership: 0.209%Jane Street Group LLCBought 45,332 shares on 2/15/2023Ownership: 0.116%Virtu Financial LLCBought 31,003 shares on 2/15/2023Ownership: 0.079%RA Capital Management L.P.Sold 3,406,853 shares on 2/14/2023Ownership: 4.107%Point72 Asset Management L.P.Sold 693,786 shares on 2/14/2023Ownership: 3.611%View All Institutional Transactions ACHL Stock - Frequently Asked Questions Should I buy or sell Achilles Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHL shares. View ACHL analyst ratings or view top-rated stocks. What is Achilles Therapeutics' stock price forecast for 2023? 3 equities research analysts have issued 1 year price objectives for Achilles Therapeutics' shares. Their ACHL share price forecasts range from $8.00 to $12.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,036.5% from the stock's current price. View analysts price targets for ACHL or view top-rated stocks among Wall Street analysts. How have ACHL shares performed in 2023? Achilles Therapeutics' stock was trading at $0.90 at the beginning of 2023. Since then, ACHL shares have decreased by 2.2% and is now trading at $0.8799. View the best growth stocks for 2023 here. Are investors shorting Achilles Therapeutics? Achilles Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 6,300 shares, a drop of 33.7% from the February 28th total of 9,500 shares. Based on an average daily volume of 445,400 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company's stock are sold short. View Achilles Therapeutics' Short Interest. When is Achilles Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our ACHL earnings forecast. How were Achilles Therapeutics' earnings last quarter? Achilles Therapeutics plc (NASDAQ:ACHL) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.14. When did Achilles Therapeutics IPO? (ACHL) raised $176 million in an initial public offering on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO. What is Achilles Therapeutics' stock symbol? Achilles Therapeutics trades on the NASDAQ under the ticker symbol "ACHL." Who are Achilles Therapeutics' major shareholders? Achilles Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (4.11%), Point72 Asset Management L.P. (3.61%), Renaissance Technologies LLC (1.24%), Millennium Management LLC (0.21%), Jane Street Group LLC (0.12%) and Virtu Financial LLC (0.08%). How do I buy shares of Achilles Therapeutics? Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Achilles Therapeutics' stock price today? One share of ACHL stock can currently be purchased for approximately $0.88. How much money does Achilles Therapeutics make? Achilles Therapeutics (NASDAQ:ACHL) has a market capitalization of $36.02 million. The company earns $-71,180,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. How many employees does Achilles Therapeutics have? The company employs 242 workers across the globe. How can I contact Achilles Therapeutics? Achilles Therapeutics' mailing address is 245 HAMMERSMITH ROAD, LONDON X0, W6 8PW. The official website for the company is www.achillestx.com. The company can be reached via phone at 44-0-20-8154-4600 or via email at ir@achillestx.com. This page (NASDAQ:ACHL) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.